Inotodiol specifically demonstrated its anti-NAFLD properties by regulating the lipid metabolism pathway, farnesoid X receptor (FXR)/small heterodimer partner (SHP)/sterol regulatory element-binding protein-1c (SREBP-1c) (Liu et al., 2016). This evidence concerns the gene NR0B2 and metabolic dysfunction-associated steatotic liver disease.